Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × NSCLC × Vinorelbine × Clear all

Phase

Status

Completed 2 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Hodgkin Disease 3 Carcinoma, Non-Small-Cell Lung 3 Rhabdomyosarcoma 2 Recurrence 2 Advanced Breast Cancer 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Lung Neoplasms 1 HER2-positive Advanced Breast Cancer 1 HER2-negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Carcinoma, Squamous Cell 1 Carcinoma, Large Cell 1 Adenocarcinoma 1

Interventions

Drug Therapy 4 Radiotherapy 3 Pemetrexed 3 Carboplatin 3 osimertinib 2 aflutinib 2 Radiosurgery 2 trilaciclib 1 toripalimab 1 tislelizumab 1 sugemalimab 1 spartalizumab 1 sintilimab 1 pembrolizumab 1 cemiplimab 1 Vinorelbine 1 Platinum 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Chemotherapy, Adjuvant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06576635 2026-01-20

LUNG-05

University of Illinois at Chicago

Phase NA Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡